Our data supports this model, indicating that HV-HP may suppress MSH6 expressions, potentially increasing microsatellite instability (MSI), which is a recognized predictive biomarker for GC prognosis and response to ICB therapy and chemotherapy (81–85). Here, MSH6 is linked to gastric cancer.